6th Annual Project & Portfolio Management in the Pharmaceutical Industry

Jacob Fleming Conferences28 - 29 September 2010, Milan, Italy.
After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies.

Testimonials
"Good balance of speakers, great learning experience and excellent chairman!"
Director Research Project Management, MedImmune, UK

"Very high-quality & influential speakers."
Portfolio Director, AstraZeneca, UK

"Very practical, inspiring and high-level agenda. Very good conclusions from the chairman."
Senior Portfolio Manager, GlaxoSmithKline, Belgium

Expert Advisors
Head of Discovery Research, Roche, Switzerland
Vice President Portfolio Management, Strategic Planning, Bayer Schering Pharma, Germany
Vice President Project Management R&D, Amgen, USA
Scientific Vice President, Novo Nordisk, Denmark
Head R&D Portfolio Management, UCB, UK
Executive Vice President & Chief Scientific Officer, Ipsen, France
Executive Vice President Research & Development, Nycomed, Germany

Key speakers
Vice President Special Operations, Worldwide Research Centers of Emphasis, Pfizer, UK
Global Head Portfolio Management & Reporting, Sanofi Aventis, France
Head Global Project Management, Abbott, Germany
Global Head of Portfolio Management & Interfaces Discovery Research and Oncology, MerckSerono, Switzerland
Head Portfolio Management, Bayer Schering Pharma, Germany
Vice President Research, Lundbeck, Denmark
Senior Project Leader Cancer Immunotherapeutics, GSK Biologicals, Belgium

Key topics

  • Explore the ways how leading Pharma companies develop their portfolios to add value to key stakeholders
  • Trends in portfolio offerings – more for physicians, payers or patients?
  • The impact of current payer-driven environment and cost-containment initiatives on managing R&D projects
  • Achieving a balanced, rich & varied portfolio in a competitive and limited resources environment
  • Innovative approaches to managing Discovery Projects
  • Project Management in Late stage Development Projects
  • Prioritization and decision analysis tools –decision making on innovation
  • Balancing the risks in Project & Portfolio Management - Risk Management in PPM
  • Enhancing the innovation & strong portfolios through R&D collaborations and M&A – the role of alliance management & business development

Who should attend
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Portfolio Management, Project Management, Pharmaceutical Development, R&D, Strategic Planning & Decision, Strategy & Portfolio Analysis, Portfolio Selection, Decision Analysis.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6thPPM?partner=worldpharmanewsPPM

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...